Nov 29, 2022 / 09:20PM GMT
Umer Raffat - Evercore Inc. - Analyst
Hey, guys. Thanks for joining us. Pleasure to have the management team from SpringWorks join us. I know there's a lot of activity coming up in the coming months but let me turn it over to you first to kick things off.
Saqib Islam - SpringWorks Therapeutics, Inc. - CEO
Thanks, Umer. Obviously, we appreciate you hosting us today at your conference. It's a pleasure to be here to share updates on SpringWorks ahead of -- as you said, it will be a busy 12 months ahead of us with data across the portfolio and potentially a drug launch upcoming in 2023. Before going into specific questions, I'd love to start with a brief overview of SpringWorks.
For those who don't know us, we are a clinical-stage oncology company committed to making a profound impact on patients suffering from severe rare diseases and cancer. We're advancing a diversified pipeline spanning our three core focus areas, which are rare tumors, multiple myeloma through BCMA combinations, and biomarker-defined metastatic solid tumors.
Our late-stage
SpringWorks Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers